Simon Žakelj

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4773838/publications.pdf

Version: 2024-02-01

26 646 13 25 papers citations h-index g-index

26 26 26 1064
all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	The Magic of Crystal Structure-Based Inhibitor Optimization: Development of a Butyrylcholinesterase Inhibitor with Picomolar Affinity and in Vivo Activity. Journal of Medicinal Chemistry, 2018, 61, 119-139.	6.4	112
2	Development of an in-vivo active reversible butyrylcholinesterase inhibitor. Scientific Reports, 2016, 6, 39495.	3.3	105
3	Multi-target-directed ligands for treating Alzheimer's disease: Butyrylcholinesterase inhibitors displaying antioxidant and neuroprotective activities. European Journal of Medicinal Chemistry, 2018, 156, 598-617.	5. 5	72
4	A review of methods for solubility determination in biopharmaceutical drug characterization. Drug Development and Industrial Pharmacy, 2019, 45, 1717-1724.	2.0	50
5	Ciprofloxacin permeability and its active secretion through rat small intestine in vitro. International Journal of Pharmaceutics, 2006, 313, 175-180.	5.2	45
6	Stereoselective Activity of 1-Propargyl-4-styrylpiperidine-like Analogues That Can Discriminate between Monoamine Oxidase Isoforms A and B. Journal of Medicinal Chemistry, 2020, 63, 1361-1387.	6.4	33
7	N-alkylpiperidine carbamates as potential anti-Alzheimer's agents. European Journal of Medicinal Chemistry, 2020, 197, 112282.	5.5	33
8	Suitability of RPMI 2650 cell models for nasal drug permeability prediction. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 145, 85-95.	4.3	25
9	In vitro interactions between aged garlic extract and drugs used for the treatment of cardiovascular and diabetic patients. European Journal of Nutrition, 2010, 49, 373-384.	3.9	24
10	The influence of buffer composition on tissue integrity during permeability experiments "in vitro― International Journal of Pharmaceutics, 2004, 272, 173-180.	5. 2	23
11	Suitability and functional characterization of two Calu-3 cell models for prediction of drug permeability across the airway epithelial barrier. International Journal of Pharmaceutics, 2020, 585, 119484.	5 . 2	22
12	Decreasing acidity in a series of aldose reductase inhibitors: 2-Fluoro-4-(1H-pyrrol-1-yl)phenol as a scaffold for improved membrane permeation. Bioorganic and Medicinal Chemistry, 2014, 22, 2194-2207.	3.0	20
13	Identification and characterization of the novel reversible and selective cathepsin X inhibitors. Scientific Reports, 2017, 7, 11459.	3.3	15
14	Treatment of canine cognitive dysfunction with novel butyrylcholinesterase inhibitor. Scientific Reports, 2021, 11, 18098.	3.3	12
15	Applicability of RPMI 2650 and Calu-3 Cell Models for Evaluation of Nasal Formulations. Pharmaceutics, 2022, 14, 369.	4.5	11
16	A Fine-Tuned Lipophilicity/Hydrophilicity Ratio Governs Antibacterial Potency and Selectivity of Bifurcated Halogen Bond-Forming NBTIs. Antibiotics, 2021, 10, 862.	3.7	9
17	Do the Recommended Standards for In Vitro Biopharmaceutic Classification of Drug Permeability Meet the "Passive Transport―Criterion for Biowaivers?. Current Drug Metabolism, 2013, 14, 21-27.	1.2	7
18	Biopharmaceutical classification of desloratadine – not all drugs are classified the easy way. Acta Pharmaceutica, 2020, 70, 131-144.	2.0	6

Simon Žakelj

#	Article	IF	CITATIONS
19	Multitarget 2′-hydroxychalcones as potential drugs for the treatment of neurodegenerative disorders and their comorbidities. Neuropharmacology, 2021, 201, 108837.	4.1	6
20	Absorption and elimination of imatinib through the rat intestine in vitro. International Journal of Pharmaceutics, 2014, 460, 144-149.	5.2	3
21	Mechanical properties and drug permeability of the PA6 membranes prepared by immersion precipitation from PA6 \hat{a} formic acid \hat{a} water system. Journal of Membrane Science, 2018, 562, 67-75.	8.2	3
22	Echinacea angustifolia DC. Lipophilic Extract Patch for Skin Application: Preparation, In Vitro and In Vivo Studies. Pharmaceutics, 2020, 12, 1096.	4.5	3
23	Do the recommended standards for in vitro biopharmaceutic classification of drug permeability meet the "passive transport" criterion for biowaivers?. Current Drug Metabolism, 2013, 14, 21-7.	1.2	3
24	The Effect of Clodronate on the Integrity and Viability of Rat Small Intestine in Vitro-A Comparison with EDTA. Biological and Pharmaceutical Bulletin, 2005, 28, 1249-1253.	1.4	2
25	Indoles and 1-(3-(benzyloxy)benzyl)piperazines: Reversible and selective monoamine oxidase B inhibitors identified by screening an in-house compound library. Bioorganic Chemistry, 2022, 119, 105581.	4.1	2
26	Thematic issue on drug delivery for specific populations. European Journal of Pharmaceutical Sciences, 2015, 75, 1.	4.0	0